ParaTech A/S is a privately held Danish corporation founded in 2004, residing on the SCION-DTU research campus North of Copenhagen. The company has research and manufacturing facilities approved by DMA for manufacturing drug product based on TSO for clinical trials. Historically, ParaTech has supplied active pharmaceutical ingredient for clinical trials conducted by third parties. These trials have involved more than 500 patients.
In 2017, the company re-organized its ownership structure, raised DKK 23 mill. from private investors and expanded its board of directors. Going forward, ParaTech will sponsor clinical trials in inflammatory diseases in addition to manufacturing TSO-based drug products. Thus, in January, 2018, DMA granted approval to begin the PROCTO-study, a phase IIb trial of a TSO-based medicinal product in patients suffering from ulcerative colitis.